2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T4c8,Mounting evidence supports the efficacy of nonpharmacologic or psychosocial interventions for reducing behavioral and psychological symptoms of dementia (BPSD), identifies the comparative risks and benefits of psychotropic medication, and underscores the importance of deprescribing psychotropic medications. However, evidence from clinical settings indicates that uptake of nonpharmacologic interventions and potential overuse of medications remain problematic. We begin by discussing the importance of exploring potential contributors to BPSD, using person-centered language to describe BPSD, implementing holistic and person-centered care plans, measuring clinically important changes in BPSD, and considering social determinants of health when assessing and managing BPSD; we also discuss the historical context informing how clinicians manage BPSD. Next, we compare and contrast nonpharmacologic and pharmacologic approaches to managing BPSD, evaluate their individual and comparative efficacy, and describe recommendations for intervention deprescribing or deimplementation. Lastly, we discuss strengths and limitations of the current evidence supporting BPSD management as well as recommendations for future research.31:T4d9,Mounting evidence supports the efficacy of nonpharmacologic or psychosocial interventions for reducing behavioral and psychological symptoms of dementia (BPSD), identifies the comparative risks and benefits of psychotropic medication, and underscores the importance of deprescribing psychotropic medications. However, evidence from clinical settings indicates that uptake of nonpharmacologic interventions and potential overuse of medications remain problematic. We begin by discussing the importance of exploring potential contributors to BPSD, using person-centered language to describe BPSD, implementing holistic and person-centered care plans, measuring clinically important changes in BPSD, and considering social determinants of health when assessing and managing BPSD; we also discuss the historical context informing how clinicians manage BPSD. Next, we compare and contrast nonpharmacologic and pharmacologic approaches to managing BPSD, evaluate their individual and comparative efficacy, and describe recommendations for intervention deprescribing or deimplementation. Lastly, we discuss strengths and limitations of the current evidence supporting BPSD management as well as recommendations for future research.32:T68a,The association between dairy intake and dementia risk remains uncertain, especially for dairy products with varying fat contents. The aim of this study was to investigate the association between high-fat and low-fat dairy intake and dementia risk. This study used data from a prospective cohort in Sweden, the Malmö Diet and Cancer cohort, which consisted of community-based participants who underwent dietary assessment at baseline (1991-1996). Dietary intake was evaluated using a comprehensive diet history method that combined a 7-day food diary, a food frequency questionnaire, and a dietary interview. Dementia cases were identified through the Swedish National Patient Register until December 31, 2020, and cases diagnosed until 2014 were further validated. The primary outcome of the study was all-cause dementia, and the secondary outcomes were Alzheimer disease (AD) and vascular dementia (VaD). Cox proportional hazard regression models were used to estimate hazard ratio (HR) and 95% CI. This study included 27,670 participants (mean baseline age 58.1 years, SD 7.6; 61% female). During a median of 25 years of follow-up, 3,208 incident dementia cases were recorded. Consumption of ≥50 g/d of high-fat cheese (>20% fat) was associated with a reduced risk of all-cause dementia (HR 0.87; 95% CI, 0.78-0.97) and VaD (HR 0.71, 95% CI 0.52-0.96) compared with lower intake (<15 g/d). An inverse association between high-fat cheese and AD was found among Higher intake of high-fat cheese and high-fat cream was associated with a lower risk of all-cause dementia, whereas low-fat cheese, low-fat cream, and other dairy products showed no significant association. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Vascular Dementia: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Vascular Dementia (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Vascular%20Dementia\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Vascular Dementia\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Vascular%20Dementia\"}]}}"}}]],["$","$L2f",null,{"title":"Vascular Dementia: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Vascular Dementia with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1002/alz.71692","pmid":"42621843","title":"Angiotensin receptor blockers and dementia risk in older adults: A target trial emulation","journal_title":"Alzheimer's & Dementia","journal_issn":"1552-5260","published_at":"2026-08-20T00:00:00.000Z","url":"https://doi.org/10.1002/alz.71692","source_score":98,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-26T06:19:54.528Z","updated_at":"2026-08-26T06:19:54.528Z","tags":[{"paper_doi":"10.1002/alz.71692","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"modality","value":"Angiotensin Receptor Blocker","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"modality","value":"Calcium Channel Blocker","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"sample_size","value":"n=52019","value_numeric":52019},{"paper_doi":"10.1002/alz.71692","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"study_design","value":"Target Trial Emulation (Retrospective Cohort)","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"warning","value":"ACE inhibitors were not included as a comparator due to low prescribing frequency in Japan, limiting generalizability to settings where ACEi are commonly used.","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"warning","value":"The lead author (H.N.) disclosed research funding and consulting fees from GlaxoSmithKline, though no direct conflict with the study drugs is noted.","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"warning","value":"The study design is labeled 'target trial emulation' using a retrospective cohort; level of evidence is observational (not a true RCT) despite rigorous methodological safeguards.","value_numeric":null},{"paper_doi":"10.1002/alz.71692","tag_type":"warning","value":"Vascular dementia subgroup had only 129 events (32 ARB, 97 CCB), so the HR of 0.617 carries wide confidence intervals and should be interpreted with caution.","value_numeric":null}],"summaries":{"what_studied":"This nationwide target trial emulation compared new initiation of angiotensin receptor blockers (ARBs) vs. calcium channel blockers (CCBs) on incident dementia risk in dementia-free Japanese adults aged ≥65 years, using the LIFE database (April 2014–September 2024), with median follow-up of 3.6 years (n=52,019).","key_result":"ARB initiation was associated with lower all-cause dementia risk vs. CCB (ITT HR 0.916, 95% CI 0.852–0.985; 5-year risk 8.0% vs. 8.8%, absolute risk difference −0.8 pp). The effect was strongest for vascular dementia (HR 0.617, 95% CI 0.409–0.930) but not statistically significant for Alzheimer's disease (HR 0.930, 95% CI 0.849–1.018). Achieved blood pressure was nearly identical between groups (<1 mmHg difference at each follow-up year).","limitations":"- Residual confounding from unmeasured factors (education, socioeconomic status, baseline cognition, BP variability) cannot be excluded.\n- Dementia diagnosis and subtype classification relied on ICD-10 administrative codes, risking nondifferential misclassification that could attenuate associations.\n- Findings are from a Japanese cohort; generalizability to other healthcare systems with different prescribing patterns is uncertain.","practice_takeaway":"When selecting a first-line antihypertensive in older adults where ARBs and CCBs are otherwise equivalent, ARB-based therapy may offer a modest cognitive benefit—particularly for vascular dementia—beyond blood pressure control alone. The absolute risk difference is small (~0.8 pp over 5 years), so individual comorbidities, tolerability, and patient preference should still guide choice."}},{"doi":"10.1016/j.ajo.2026.07.051","pmid":"42546867","title":"Glaucoma and Neurodegenerative Disease Risk: A 10-Year Assessment of Real-World Global Data","journal_title":"American Journal of Ophthalmology","journal_issn":"0002-9394","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1016/j.ajo.2026.07.051","source_score":11,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-12T13:26:17.461Z","updated_at":"2026-08-12T13:26:17.461Z","tags":[{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Glaucoma","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Mild Cognitive Impairment","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Normal-Tension Glaucoma","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Parkinson's Disease","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Primary Angle-Closure Glaucoma","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Primary Open-Angle Glaucoma","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"sample_size","value":"n=768512","value_numeric":768512},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"warning","value":"Sample size reported as matched pairs (384,256 pairs = ~768,512 total individuals); value_numeric set to total individuals for accuracy, but the paper emphasizes pairs.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"warning","value":"Study design label 'Retrospective Cohort Study' is clear, but the use of a federated claims/EHR network (TriNetX) introduces potential for coding bias and variable data quality across institutions.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"warning","value":"Subtype-specific sample sizes are not reported, so statistical power for PACG and NTG subgroup analyses is uncertain.","value_numeric":null},{"paper_doi":"10.1016/j.ajo.2026.07.051","tag_type":"warning","value":"The overall AD association (HR 1.485) appears driven by factors beyond the three named subtypes, since none of POAG, PACG, or NTG individually showed significant AD associations — this discrepancy is noted in the paper but not fully explained.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used TriNetX global data (2005–2025) to assess 10-year risk trajectories of neurodegenerative diseases (MCI, Alzheimer's disease, vascular dementia, unspecified dementias, Parkinson's disease) in 384,256 propensity-matched glaucoma–control pairs, stratified by age onset (<45 vs >65 years) and glaucoma subtype (POAG, PACG, NTG).","key_result":"Glaucoma was associated with elevated 10-year risks for AD (HR 1.485), vascular dementia (HR 1.213), and Parkinson's disease (HR 1.115, peaking at 10 years); early-onset glaucoma showed a notably high AD risk at 10 years (HR 2.320). By subtype, NTG was the only subtype with a significant Parkinson's disease link (HR 1.283), while AD associations were non-significant across all three individual subtypes.","limitations":"- Observational design from a real-world database precludes causal inference; associations may reflect shared risk factors or surveillance bias.\n- ICD-10 code–based outcome ascertainment may undercount or misclassify neurodegenerative diagnoses.\n- Subtype-level analyses (especially PACG and NTG) likely had smaller sample sizes, reducing power for some comparisons.","practice_takeaway":"Clinicians managing glaucoma patients—especially those with early-onset disease or NTG—should maintain a low threshold for neurocognitive screening, given the observed associations with dementia and Parkinson's disease over 10 years. These findings are correlational, not causal, so they should inform monitoring rather than change treatment targets."}},{"doi":"10.1212/wnl.0000000000218313","pmid":"42525901","title":"Association of Sugar Restriction in Utero Through Age 2 Years on Dementia Risk Later in Life","journal_title":"Neurology","journal_issn":"0028-3878","published_at":"2026-07-29T00:00:00.000Z","url":"https://doi.org/10.1212/wnl.0000000000218313","source_score":424,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-06T13:22:16.381Z","updated_at":"2026-08-06T13:22:16.381Z","tags":[{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"condition","value":"Alzheimer Disease","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"modality","value":"Dietary Intervention","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"sample_size","value":"n=64737","value_numeric":64737},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"study_design","value":"Natural Experiment / Cohort Study","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"warning","value":"The AD result for in utero + first year of life just crosses the null (HR 0.77; 95% CI 0.59–1.00), so that specific estimate should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously — the findings are observational and based on a historical cohort; direct clinical translation requires further validation.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"warning","value":"The natural experiment design (UK sugar rationing end) strengthens causal inference compared to a simple observational study, but residual confounding from other wartime/post-war differences (e.g., nutrition, socioeconomic status, stress) cannot be fully excluded.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218313","tag_type":"warning","value":"UK Biobank is a volunteer cohort with known healthy-volunteer bias, which may attenuate or distort the true effect sizes.","value_numeric":null}],"summaries":{"what_studied":"Using the abrupt end of UK sugar rationing in September 1953 as a natural experiment, this study evaluated whether sugar restriction during different windows in the first 1,000 days (in utero and/or early childhood) was associated with adult risk of all-cause dementia, Alzheimer disease (AD), and vascular dementia (VaD) in 64,737 UK Biobank participants (mean age 54.6 years at recruitment, 56.4% women).","key_result":"Exposure to sugar rationing in utero plus the first 2 years of life was associated with 23% lower hazard of all-cause dementia (HR 0.77; 95% CI 0.63–0.95) and 28% lower hazard of AD (HR 0.72; 95% CI 0.53–0.98), with delayed dementia onset of ~2.55 years (all-cause), ~2.87 years (AD), and ~2.49 years (VaD); also linked to higher gray matter volume, lower white matter hyperintensity volume, and better cognitive performance. Type 2 diabetes and hypertension jointly mediated 25.5% of the association.","limitations":"- Observational design using a natural experiment cannot fully rule out unmeasured confounders (e.g., other wartime dietary or socioeconomic differences between exposed and unexposed cohorts).\n- Dementia ascertainment relied on linked ICD-10 records, which may undercount cases or introduce detection bias.\n- UK Biobank participants are healthier and more educated than the general population, limiting generalizability.","practice_takeaway":"Reducing added sugar intake in the first 1,000 days of life — from conception through age 2 — may be a modifiable strategy to lower long-term dementia risk. Clinicians counseling pregnant patients and parents of young children should reinforce existing guidelines to minimize early-life sugar exposure."}},{"doi":"10.1212/wnl.0000000000218352","pmid":"42485607","title":"Associations of Alzheimer Disease and Related Dementia Neuropathologies With Timely Diagnosis of Dementia in Healthcare Settings","journal_title":"Neurology","journal_issn":"0028-3878","published_at":"2026-07-22T00:00:00.000Z","url":"https://doi.org/10.1212/wnl.0000000000218352","source_score":23,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-29T06:19:21.412Z","updated_at":"2026-08-29T06:19:21.412Z","tags":[{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"condition","value":"Alzheimer Disease","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"condition","value":"LATE-NC (Limbic-Predominant Age-Related TDP-43 Encephalopathy)","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"condition","value":"Lewy Body Disease","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"sample_size","value":"n=500","value_numeric":500},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"warning","value":"Neuropathologic burden was assessed postmortem; causal direction and applicability to in vivo clinical settings cannot be confirmed without biomarker-based replication.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"warning","value":"No proprietary drugs or therapeutic modalities were evaluated; modality and brand/generic tags are not applicable to this study.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"warning","value":"The impact_flag 'safety_signal' is used here to flag the systematic underdiagnosis pattern (46% of participants missed timely diagnosis), particularly for vascular and Lewy body dementia subtypes, which has direct patient safety implications.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000218352","tag_type":"warning","value":"The study is heavily skewed toward non-Latino White, highly educated participants (95% White); findings may not apply to Black, Latino, or less-educated populations.","value_numeric":null}],"summaries":{"what_studied":"This retrospective study examined whether specific postmortem neuropathologies (AD, LATE-NC, vascular pathologies, neocortical Lewy bodies) were associated with receiving a timely dementia diagnosis in Medicare claims, defined as a diagnosis within 3 years before or 1 year after cohort-determined dementia onset, among 500 deceased older adults from 5 Rush Alzheimer's Disease Center cohorts linked to Medicare data (dementia onset through 2019).","key_result":"Only 54% (272/500) received a timely diagnosis. In fully adjusted models, pathologic AD (OR 1.91, 95% CI 1.21–3.00) and moderate/severe LATE-NC (OR 1.83, 95% CI 1.25–2.68) independently doubled the odds of timely diagnosis, while vascular pathologies (OR 0.94) and neocortical Lewy bodies (OR 1.00) did not. Having 3 or 4 co-pathologies raised the odds over 2-fold (OR 2.24, 95% CI 1.32–3.82) vs. 0–1 pathology.","limitations":"- Sample is 95% non-Latino White, highly educated, and drawn from research volunteers who consented to brain donation and Medicare linkage, limiting generalizability.\n- Neuropathologies were measured postmortem; the study assumes pathology severity at autopsy reflects burden at dementia onset.\n- Modest sample size (n=500) precluded analysis of all possible mixed-pathology combinations and firm conclusions about whether copathology burden vs. specific marker inclusion drives the association.","practice_takeaway":"Clinicians should be aware that dementia driven by vascular pathology or Lewy body disease is roughly half as likely to be captured in a timely fashion as AD or LATE-NC—suggesting a need for broader screening tools that go beyond memory-focused tests to detect executive and visuospatial deficits. Recognizing this diagnostic gap may prompt earlier evaluation in patients with atypical or non-amnestic presentations."}},{"doi":"10.1186/s12974-026-03957-2","pmid":"42477693","title":"Subcutaneous transplantation of lung organoids ameliorates vascular dementia via the IGFBP7-Ago2 mediated lung-brain axis","journal_title":"Journal of Neuroinflammation","journal_issn":"1742-2094","published_at":"2026-07-20T00:00:00.000Z","url":"https://doi.org/10.1186/s12974-026-03957-2","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-29T13:31:16.898Z","updated_at":"2026-07-29T13:31:16.898Z","tags":[{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"condition","value":"Chronic Cerebral Hypoperfusion","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"generic","value":"IGFBP7","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"modality","value":"Organoid Transplantation","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"study_design","value":"Preclinical Animal Study","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"warning","value":"Sample size (number of mice per group) is not reported in the abstract; tagging was omitted accordingly.","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"warning","value":"Sex of the animal subjects is not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"warning","value":"Study is entirely preclinical (mouse BCAS model); no human data are presented. Clinical applicability is speculative at this stage.","value_numeric":null},{"paper_doi":"10.1186/s12974-026-03957-2","tag_type":"warning","value":"The DOI prefix '10.1186/s12974-026-03957-2' uses a non-standard year format (026); this may be a typographical error in the source metadata.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated whether subcutaneous transplantation of lung organoids (LO) could ameliorate vascular dementia (VaD) in a mouse model of bilateral common carotid artery stenosis (BCAS), and investigated the mechanistic role of the IGFBP7-Ago2 axis in lung-brain crosstalk.","key_result":"LO transplantation restored circulating IGFBP7 levels in BCAS mice, reduced neuroinflammation and neurovascular damage, improved cognitive function, and concurrently reversed peripheral lung injury — with recovery of endogenous pulmonary IGFBP7 expression — identifying the IGFBP7-Ago2 axis as a core regulatory pathway of the lung-brain axis.","limitations":"- Findings are limited to a mouse (BCAS) model; clinical translation to humans is unproven.\n- Mechanistic studies rely on organoid transplantation in animals; the efficacy and safety profile in human subjects is unknown.\n- No direct comparison to existing pharmacological or other biotherapy approaches for VaD was reported.","practice_takeaway":"While still preclinical, this study identifies IGFBP7 as a potential therapeutic target and lung organoid transplantation as a novel biotherapy avenue for vascular dementia — a condition with no currently approved disease-modifying treatments. Clinicians should watch for translational follow-up studies validating this lung-brain axis approach."}},{"doi":"10.1001/jamanetworkopen.2026.24175","pmid":"42475091","title":"Spousal Dementia Exposure and Risk of Dementia","journal_title":"JAMA Network Open","journal_issn":"2574-3805","published_at":"2026-07-20T00:00:00.000Z","url":"https://doi.org/10.1001/jamanetworkopen.2026.24175","source_score":233,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-27T14:09:13.430Z","updated_at":"2026-07-27T14:09:13.430Z","tags":[{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"category","value":"Medicine, General & Internal","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"condition","value":"Alzheimer Disease","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"sample_size","value":"n=955105","value_numeric":955105},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"study_design","value":"Population-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"warning","value":"No pharmacological intervention was studied; the 'modality', 'brand', and 'generic' tags are not applicable. The impact_flag 'practice_changing' is assigned because this large-scale study provides the strongest evidence to date for elevated dementia risk in spousal caregivers with absolute risk quantification, but the causal mechanism remains unestablished.","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"warning","value":"Shared genetic risk between long-term spouses (assortative mating) cannot be fully ruled out as a contributor to the association.","value_numeric":null},{"paper_doi":"10.1001/jamanetworkopen.2026.24175","tag_type":"warning","value":"The study is restricted to Taiwan's married population; results may not generalize to Western or non-Asian populations or to unmarried cohabiting partners.","value_numeric":null}],"summaries":{"what_studied":"This nationwide cohort study examined whether having a spouse with incident dementia raises one's own dementia risk, and whether that risk varies by sex, age, income, urbanicity, and number of children — using Taiwan's National Health Insurance Research Database (1998–2022) with 955,105 matched individuals.","key_result":"Spousal dementia exposure significantly raised all-cause dementia risk: HR 1.74 (95% CI, 1.70–1.78) for women (+2.75 percentage points over 5 years) and HR 1.69 (95% CI, 1.64–1.73) for men (+3.49 percentage points over 5 years). Relative risk was higher at younger ages; absolute risk differences grew with age. Higher income and more children attenuated the association.","limitations":"- Study population is limited to married individuals in Taiwan, limiting generalizability to other cultural or family structures.\n- Administrative claims data may underdiagnose dementia, especially mild cases.\n- Matching on income and urbanicity may not fully control for shared lifestyle, environmental, or genetic confounders within couples.","practice_takeaway":"Clinicians should recognize that caregiving spouses of dementia patients are themselves at meaningfully elevated dementia risk — nearly 70–74% higher relative risk — and consider proactive cognitive screening and support for this group, particularly older adults and those with lower income or fewer social supports."}},{"doi":"10.1111/dom.71123","pmid":"42472674","title":"Age of Type 1 Diabetes Onset and Dementia Risk: A Swedish Nationwide, Register‐Based Cohort Study","journal_title":"Diabetes, Obesity and Metabolism","journal_issn":"1462-8902","published_at":"2026-07-19T00:00:00.000Z","url":"https://doi.org/10.1111/dom.71123","source_score":15,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-01T13:22:01.139Z","updated_at":"2026-08-01T13:22:01.139Z","tags":[{"paper_doi":"10.1111/dom.71123","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"sample_size","value":"n=43440","value_numeric":43440},{"paper_doi":"10.1111/dom.71123","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"warning","value":"Dementia subtype analyses (Alzheimer's, vascular, non-Alzheimer's-non-vascular) are mentioned in the methods but subtype-specific HRs are not reported in the provided abstract or results — clinicians should consult the full text for those breakdowns.","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"warning","value":"No drug or therapeutic modality is evaluated; modality and brand/generic tags are not applicable here.","value_numeric":null},{"paper_doi":"10.1111/dom.71123","tag_type":"warning","value":"The absolute dementia rate (1.2%) is low, which may reflect the relatively young mean age of the cohort (33 years); risk may be substantially higher with longer follow-up as cohorts age.","value_numeric":null}],"summaries":{"what_studied":"This Swedish nationwide prospective cohort study examined whether younger age at Type 1 diabetes (T1D) onset — stratified as <10, 10–17, and 18–30 years — was associated with all-cause dementia risk, using Cox regression with age as the time-axis over a median 29.3 years of follow-up.","key_result":"T1D onset before age 10 was associated with a 37% higher risk of all-cause dementia compared to onset at 18–30 years (HR 1.37, 95% CI 1.08–1.73); onset between 10–17 years showed no significant increase (HR 1.04, 95% CI 0.85–1.26). Only 1.2% (530/43,440) developed dementia overall.","limitations":"- Observational design limits causal inference; residual confounding cannot be excluded.\n- Dementia was ascertained by ICD-10 codes from registries, which may miss mild or undiagnosed cases.\n- The study population was exclusively Swedish, which may limit generalizability to other ethnicities or healthcare systems.","practice_takeaway":"Children diagnosed with T1D before age 10 carry a meaningfully elevated long-term dementia risk — clinicians should consider early and sustained attention to modifiable risk factors (e.g., glycemic control, cardiovascular health) in this group. Dementia screening awareness may be warranted as these patients age."}},{"doi":"10.1038/s41380-026-03703-3","pmid":"42337012","title":"Metabolomic signatures of brain aging: A multimodal and genetic study","journal_title":"Molecular Psychiatry","journal_issn":"1359-4184","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1038/s41380-026-03703-3","source_score":48,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-07T13:26:12.675Z","updated_at":"2026-07-07T13:26:12.675Z","tags":[{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Anxiety","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Brain Aging","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Depression","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Parkinson's Disease","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Stroke","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"generic","value":"glucose","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"modality","value":"Genome-Wide Association Study","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"modality","value":"Metabolomics","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"modality","value":"Neuroimaging","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"sample_size","value":"n=37458","value_numeric":37458},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"study_design","value":"Cross-Sectional Study with Mendelian Randomization","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"warning","value":"Full text provided in the paper appears to be supplementary figures only; the main manuscript body was not included, so some methodological details may be inferred from the abstract alone.","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"warning","value":"The 'impact_flag' of practice_changing is applied cautiously — glucose is already a clinical target, but this study adds brain aging as a specific outcome domain rather than overturning existing practice.","value_numeric":null},{"paper_doi":"10.1038/s41380-026-03703-3","tag_type":"warning","value":"The study design is primarily cross-sectional for metabolite–BAG associations despite using longitudinal UK Biobank waves; causal claims rely on Mendelian randomization, not prospective intervention data.","value_numeric":null}],"summaries":{"what_studied":"This study examined the metabolic underpinnings of brain aging by integrating multimodal MRI (1,079 imaging-derived phenotypes), plasma metabolomics, and genomic data from UK Biobank participants. Machine learning models predicted brain age gap (BAG), which was then linked to plasma metabolites, genetic variants, and clinical outcomes over a lifespan timeframe.","key_result":"A LASSO regression model achieved best brain age prediction (MAE = 3.26 years, R² = 0.68). Nine plasma metabolites were significantly associated with BAG after Bonferroni correction (N = 21,780); glucose showed the strongest effect (β = 0.32, P = 9.90 × 10⁻¹²). GWAS identified 392 BAG-associated SNPs (P < 5 × 10⁻⁸), and Mendelian randomization supported a potential causal role of glucose in accelerating brain aging. Higher glucose was positively linked to 7 brain disorders (including all-cause dementia, Alzheimer's disease, vascular dementia, Parkinson's disease, stroke, depression, and anxiety) and negatively linked to cognitive performance and regional brain volumes across 80 cortical, subcortical, and cerebellar regions.","limitations":"The study is observational and largely cross-sectional for metabolite–BAG associations; NMR and MRI data were collected across different assessment waves, introducing temporal gaps between plasma and imaging measurements. Mendelian randomization assumptions (e.g., no pleiotropy) may not fully hold, limiting causal inference strength.","practice_takeaway":"Elevated plasma glucose appears to accelerate brain aging and is linked to multiple neuropsychiatric and neurodegenerative disorders — clinicians should consider glucose management as a potentially modifiable target for preserving brain health. Monitoring glycemic status may be especially relevant in patients at risk for dementia, stroke, depression, or Parkinson's disease."}},{"doi":"10.1007/s12072-026-11112-5","pmid":"42337153","title":"Alcohol consumption and dementia risk in steatotic liver disease: a nationwide cohort study","journal_title":"Hepatology International","journal_issn":"1936-0533","published_at":"2026-06-23T00:00:00.000Z","url":"https://doi.org/10.1007/s12072-026-11112-5","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-25T13:25:18.329Z","updated_at":"2026-06-25T13:25:18.329Z","tags":[{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"condition","value":"Alcohol-Related Liver Disease","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"condition","value":"Metabolic Dysfunction-Associated Steatotic Liver Disease","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"condition","value":"Steatotic Liver Disease","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"sample_size","value":"n=3071829","value_numeric":3071829},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"study_design","value":"Nationwide Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"warning","value":"SLD subtype classification used the Fatty Liver Index (FLI) rather than imaging or biopsy, which may introduce misclassification.","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"warning","value":"The cohort is exclusively Korean (National Health Insurance Service data), limiting generalizability to other ethnic populations.","value_numeric":null},{"paper_doi":"10.1007/s12072-026-11112-5","tag_type":"warning","value":"The 'practice_changing' impact flag was applied cautiously — findings are observational and the authors explicitly call for further validation before clinical guidance changes.","value_numeric":null}],"summaries":{"what_studied":"This nationwide cohort study examined dementia risk (all-cause, Alzheimer's disease, and vascular dementia) across steatotic liver disease (SLD) subtypes — MASLD, MetALD, and ALD — in 3,071,829 Korean adults without baseline dementia, followed from a 2012 health examination over a median of 5.4 years.","key_result":"72,545 all-cause dementia, 56,999 AD, and 8,923 vascular dementia cases occurred. ALD carried the highest dementia risk across all outcomes, followed by MASLD. MetALD showed largely neutral associations, except for a modest increase in vascular dementia risk. Within MASLD, the no-alcohol subgroup had consistently elevated risk for all dementia types; moderate (within-threshold) alcohol intake showed mixed results.","limitations":"- SLD classification relied on a single baseline health exam; longitudinal changes in liver or alcohol status were not tracked.\n- Alcohol intake was self-reported and subject to underreporting bias.\n- Residual confounding from unmeasured factors (e.g., diet, genetics, education) cannot be excluded.","practice_takeaway":"Patients with ALD or MASLD — especially those who abstain from alcohol — should be considered at elevated dementia risk and monitored accordingly. The neutral-to-modest signal in MetALD suggests alcohol's interaction with metabolic liver disease is complex, warranting individualized counseling rather than blanket guidance."}},{"doi":"10.1186/s12882-026-05076-9","pmid":"42204658","title":"Impact of CKD and COPD co-existence on mortality, vascular dementia, and Alzheimer’s dementia; a comparative cohort study","journal_title":"BMC Nephrology","journal_issn":"1471-2369","published_at":"2026-05-27T00:00:00.000Z","url":"https://doi.org/10.1186/s12882-026-05076-9","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-03T13:44:42.733Z","updated_at":"2026-06-03T13:44:42.733Z","tags":[{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"condition","value":"Chronic Kidney Disease","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"condition","value":"Chronic Obstructive Pulmonary Disease","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"sample_size","value":"n=468634","value_numeric":468634},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"warning","value":"Propensity score matching reduces but does not eliminate confounding from unmeasured variables (e.g., medication use, COPD severity, CKD progression rate) in this claims/EHR-based dataset.","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"warning","value":"The apparently lower Alzheimer's disease hazard in the CKD+COPD group is likely a competing-risk artefact due to higher mortality — the authors themselves caution against causal interpretation.","value_numeric":null},{"paper_doi":"10.1186/s12882-026-05076-9","tag_type":"warning","value":"The matched sample size (n=234,317 per cohort) is used for tagging; the total pre-match population was ~1.09 million.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used the TriNetX Global Network to compare outcomes in adults aged 18–80 with CKD stages 3–5 who had coexisting COPD (n=234,317 after 1:1 propensity score matching) versus CKD alone, over up to 5 years of follow-up. Outcomes were all-cause mortality, non-Alzheimer's dementia, vascular dementia, and Alzheimer's disease.","key_result":"CKD + COPD was linked to higher all-cause mortality (18.5% vs. 14.5%; HR 1.17, 95% CI 1.16–1.19) and higher non-Alzheimer's dementia (4.6% vs. 3.9%; HR 1.07, 95% CI 1.04–1.10). Alzheimer's disease appeared less frequent in the COPD group (HR 0.85, 95% CI 0.80–0.91), but this likely reflects competing mortality rather than a protective effect. No significant difference was seen for vascular dementia alone.","limitations":"- Short maximum follow-up (5 years) limits detection of dementia outcomes, which typically develop over decades.\n- Higher competing mortality in the COPD group likely distorts the apparently lower Alzheimer's hazard.\n- Retrospective ICD-10 coding from a federated network may misclassify disease severity and introduce unmeasured confounding.","practice_takeaway":"Patients with both CKD and COPD carry meaningfully higher risks of death and non-Alzheimer's dementia than those with CKD alone — clinicians should prioritise aggressive management of both conditions and consider early cognitive surveillance in this group. The seemingly lower Alzheimer's risk in CKD+COPD should not be reassuring, as it is most likely driven by higher competing mortality."}},{"doi":"10.1016/j.inpsyc.2026.100221","pmid":"42185186","title":"Automating collateral histories in dementia: Development and proof‑of‑concept evaluation of the LUMEN conversational AI","journal_title":"International Psychogeriatrics","journal_issn":"1041-6102","published_at":"2026-05-25T00:00:00.000Z","url":"https://doi.org/10.1016/j.inpsyc.2026.100221","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-31T13:35:37.742Z","updated_at":"2026-05-31T13:35:37.742Z","tags":[{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"category","value":"Psychology, Clinical","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"condition","value":"Dementia with Lewy Bodies","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"condition","value":"Frontotemporal Dementia","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"condition","value":"Mild Cognitive Impairment","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"generic","value":"Qwen3-30B-A3B","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"modality","value":"Conversational Artificial Intelligence","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"modality","value":"Large Language Model","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"sample_size","value":"n=54","value_numeric":54},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"study_design","value":"Proof-of-Concept Study","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"warning","value":"All 54 dialogues were synthetic — either clinician role-played or GPT-4 generated — so reported AUROC and κ values reflect performance on artificial data only, not real patient or carer interactions.","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"warning","value":"Qwen3-30B-A3B is an open-source LLM used as the backbone; it is not a licensed clinical device and its tag as 'generic' is an approximation given no standard drug/device classification applies.","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"warning","value":"Study design is best described as a proof-of-concept/feasibility evaluation; it does not fit neatly into standard evidence hierarchy levels — level 5 is an approximation.","value_numeric":null},{"paper_doi":"10.1016/j.inpsyc.2026.100221","tag_type":"warning","value":"The sample size tag reflects the number of synthetic dialogues (n=54), not a patient cohort; the stakeholder co-design programme involved ~232 participants but these were not diagnostic test subjects.","value_numeric":null}],"summaries":{"what_studied":"The LUMEN conversational AI system was developed and evaluated as a tool to automate structured collateral history collection from carers for dementia diagnosis, using 54 synthetic dialogues generated from 6 clinician-authored vignettes covering Alzheimer's disease, dementia with Lewy bodies, vascular dementia, frontotemporal dementia, mild cognitive impairment, and normal cognition.","key_result":"In a closed-loop synthetic proof-of-concept, macro-average AUROC was 0.95; AUROC was highest for Alzheimer's disease and vascular dementia (1.00) and lowest for mild cognitive impairment (0.77). Rule-based rubric vs. clinician rating agreement was κ = 0.88 (95% CI 0.83–0.93). Mean System Usability Scale score was 78.1/100.","limitations":"All testing used synthetic vignettes and AI-generated dialogues, not real patients or carers — results cannot be generalised to real-world diagnostic performance. The dataset was small (54 dialogues) and closed-loop, meaning the same LLM ecosystem generated and evaluated content. No prospective clinical validation has been performed.","practice_takeaway":"LUMEN shows early promise as a structured collateral history tool for memory services, but clinicians should treat these findings as proof-of-concept only. Real-world clinical trials are needed before this system can be considered for routine use."}},{"doi":"10.1002/alz.71280","pmid":"42126002","title":"Metabolomic ageing (MileAge) in mid‐life predicts incident vascular, unspecified and all‐cause dementia","journal_title":"Alzheimer's & Dementia","journal_issn":"1552-5260","published_at":"2026-05-13T00:00:00.000Z","url":"https://doi.org/10.1002/alz.71280","source_score":73,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-16T13:22:24.628Z","updated_at":"2026-05-16T13:22:24.628Z","tags":[{"paper_doi":"10.1002/alz.71280","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"modality","value":"Metabolomic Biomarker","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"sample_size","value":"n=223496","value_numeric":223496},{"paper_doi":"10.1002/alz.71280","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"warning","value":"Excluding participants on lipid-modifying treatments attenuated most associations to non-significance, suggesting lipid-related metabolites may partly drive the MileAge–dementia link and that treatment effects could confound findings.","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"warning","value":"MileAge delta was not significantly associated with incident Alzheimer's disease as a hazard outcome, but was associated with earlier Alzheimer's onset—these distinct findings should not be conflated.","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"warning","value":"The MileAge clock was trained and tested within UK Biobank, raising concern about overfitting and limiting external validity; results should be interpreted as preliminary until independently replicated.","value_numeric":null},{"paper_doi":"10.1002/alz.71280","tag_type":"warning","value":"UK Biobank is a healthy-volunteer cohort with known selection bias; survival and health-related selection into the cohort may have influenced both metabolomic profiles and dementia ascertainment.","value_numeric":null}],"summaries":{"what_studied":"In 223,496 UK Biobank participants (mean age ~57 years, median follow-up 13.7 years), this prospective cohort study tested whether mid-life plasma metabolomic age exceeding chronological age (MileAge delta) predicts incident dementia subtypes, age of onset, and whether it interacts with APOE genotype and dementia polygenic scores.","key_result":"3,976 participants developed dementia. A MileAge delta ≥1 SD above the mean was linked to higher hazards of vascular dementia (HR = 1.61, 95% CI 1.28–2.02), unspecified dementia (HR = 1.54, 95% CI 1.22–1.93), and all-cause dementia (HR = 1.24, 95% CI 1.11–1.39) vs. those ≥1 SD below the mean. No significant association with Alzheimer's disease incidence was found. Higher MileAge delta was also linked to earlier onset across diagnoses. Those with high MileAge delta plus APOE ε4/ε4 had a 10.30-fold higher all-cause dementia risk (95% CI 7.95–13.34).","limitations":"- Dementia ascertained from routine health records, introducing likely misclassification and differential diagnostic capture across data sources.\n- MileAge clock developed and validated within the same cohort (UK Biobank), limiting external generalizability; replication in independent cohorts is needed.\n- Observational design precludes causal inference; residual confounding and reverse causality cannot be fully excluded.","practice_takeaway":"A plasma-based metabolomic age score (MileAge delta) measured in mid-life may help flag patients at elevated vascular and all-cause dementia risk—especially those who also carry APOE ε4 alleles—before symptoms appear. Clinicians should watch for emerging tools combining metabolomic and genetic risk scores for earlier dementia risk stratification, though these require prospective validation before clinical use."}},{"doi":"10.1002/alz.71407","pmid":"42050365","title":"Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older","journal_title":"Alzheimer's & Dementia","journal_issn":"1552-5260","published_at":"2026-04-28T00:00:00.000Z","url":"https://doi.org/10.1002/alz.71407","source_score":43,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-08T13:23:39.095Z","updated_at":"2026-05-08T13:23:39.095Z","tags":[{"paper_doi":"10.1002/alz.71407","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"brand","value":"Shingrix","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"generic","value":"zoster vaccine recombinant, adjuvanted","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"modality","value":"Recombinant Subunit Vaccine","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"sample_size","value":"n=1,508,535","value_numeric":1508535},{"paper_doi":"10.1002/alz.71407","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"warning","value":"Level of evidence assigned as 3 (observational cohort); causal inference is not established.","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"warning","value":"Study was funded by GSK (Shingrix manufacturer); three co-authors are GSK employees holding financial equity in GSK—interpret results with this conflict of interest in mind.","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"warning","value":"The ~3-month average delay in dementia onset is a secondary descriptive finding and should not be interpreted as a precise therapeutic effect size.","value_numeric":null},{"paper_doi":"10.1002/alz.71407","tag_type":"warning","value":"The matched comparator group used preventive care visitors, which may not fully eliminate healthy-user bias despite IPTW adjustment.","value_numeric":null}],"summaries":{"what_studied":"This cohort study evaluated the risk of new-onset dementia (overall, Alzheimer's disease [AD], and vascular dementia [VD]) among US Medicare beneficiaries ≥65 years old who completed a two-dose recombinant zoster vaccine (RZV) series (n=502,845) versus matched RZV-unvaccinated comparators who had a preventive care visit (n=1,005,690), with follow-up through December 2022.","key_result":"RZV-exposed individuals had a dementia incidence of 10.45 per 1,000 person-years vs. 15.73 in unvaccinated comparators. Time-dependent HRs for ≤3/> 3 years follow-up were: dementia 0.67 (95% CI 0.65–0.68) / 0.74 (0.69–0.79); AD 0.72 (0.69–0.74) / 0.83 (0.74–0.94); VD 0.67 (0.64–0.70) / 0.66 (0.57–0.78). Average delay in dementia onset was ~3 months.","limitations":"- Observational design; unmeasured confounders (education, physical activity, marital status) cannot be excluded, though E-value analysis requires an unmeasured risk ratio ≥2.35 to explain away findings.\n- Outcome ascertainment relied on claims codes without chart validation (algorithm specificity 93–98%, sensitivity 31–79%).\n- Cohort is ~93% White, limiting generalizability to other racial/ethnic groups.","practice_takeaway":"Completing the two-dose RZV series (Shingrix) in patients ≥65 years is associated with a 26–33% lower risk of new-onset dementia across multiple subtypes—an additional reason beyond shingles prevention to counsel eligible older adults on vaccination. Results were consistent across age groups, sexes, and multiple sensitivity analyses."}},{"doi":"10.1146/annurev-clinpsy-061724-085912","pmid":"41678258","title":"Management of Behavioral and Psychological Symptoms of Dementia: Nonpharmacologic and Pharmacologic Interventions","journal_title":"Annual Review of Clinical Psychology","journal_issn":"1548-5943","published_at":"2026-02-12T00:00:00.000Z","url":"https://doi.org/10.1146/annurev-clinpsy-061724-085912","source_score":12,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-10","doi":"10.1146/annurev-clinpsy-061724-085912","days":"7","issn":"1548-5943","rank":"7","field":"Clinical Medicine","score":"12","category":"Psychology, Clinical","categories":["Psychology, Clinical"],"_categories":["Psychology, Clinical"]},"pubmed":{"doi":"10.1146/annurev-clinpsy-061724-085912","title":"Management of Behavioral and Psychological Symptoms of Dementia: Nonpharmacologic and Pharmacologic Interventions.","journal":"Annual review of clinical psychology","methods":"","results":"","abstract":"$30","keywords":["behavioral and psychological symptoms of dementia","behavioral symptoms","dementia","patient-centered care"],"pubmed_id":"41678258","conclusions":"","publication_date":"2026-02-12T00:00:00"},"crossref":{"DOI":"10.1146/annurev-clinpsy-061724-085912","URL":"https://doi.org/10.1146/annurev-clinpsy-061724-085912","ISSN":["1548-5943","1548-5951"],"link":[{"URL":"https://www.annualreviews.org/content/journals/10.1146/annurev-clinpsy-061724-085912?crawler=true&mimetype=application/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"397-425","type":"journal-article","issue":"1","score":1,"title":["Management of Behavioral and Psychological Symptoms of Dementia: Nonpharmacologic and Pharmacologic Interventions"],"author":[{"given":"Jennifer A.","family":"Watt","sequence":"first","affiliation":[{"name":"1Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada"},{"name":"2Division of Geriatric Medicine, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; email: jennifer.watt@utoronto.ca"},{"name":"3Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}]},{"given":"Zahinoor","family":"Ismail","sequence":"additional","affiliation":[{"name":"4Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada"},{"name":"5O'Brien Institute of Public Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"6Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada"}]},{"given":"Natasha","family":"Lane","sequence":"additional","affiliation":[{"name":"7Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"8Edwin S.H. Leong Centre for Healthy Aging, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}]},{"given":"Dallas","family":"Seitz","sequence":"additional","affiliation":[{"name":"9Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"10Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}]},{"given":"Zahra","family":"Goodarzi","sequence":"additional","affiliation":[{"name":"4Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada"},{"name":"5O'Brien Institute of Public Health, University of Calgary, Calgary, Alberta, Canada"},{"name":"11Division of Geriatric Medicine, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"12Division of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada"}]}],"issued":{"date-parts":[[2026,5,7]]},"member":"22","prefix":"10.1146","source":"Crossref","volume":"22","created":{"date-time":"2026-02-12T17:01:06Z","timestamp":1770915666000,"date-parts":[[2026,2,12]]},"indexed":{"date-time":"2026-05-08T03:14:18Z","timestamp":1778210058443,"date-parts":[[2026,5,8]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc-nd/4.0","start":{"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000,"date-parts":[[2026,5,7]]},"delay-in-days":0,"content-version":"unspecified"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://www.annualreviews.org/content/journals/10.1146/annurev-clinpsy-061724-085912"}},"subtitle":[],"deposited":{"date-time":"2026-05-08T02:43:45Z","timestamp":1778208225000,"date-parts":[[2026,5,8]]},"issn-type":[{"type":"print","value":"1548-5943"},{"type":"electronic","value":"1548-5951"}],"published":{"date-parts":[[2026,5,7]]},"publisher":"Annual Reviews","reference":[{"DOI":null,"key":"B1","year":"2015","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jgs.13702","key":"B2","year":"2015","issue":null,"author":null,"volume":"63","first-page":"2227","unstructured":null,"article-title":"American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","journal-title":"J. Am. Geriatr. Soc.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B3","year":"2017","issue":null,"author":null,"volume":"55","first-page":"727","unstructured":null,"article-title":"The effect of escitalopram on mood and cognition in depressive Alzheimer's disease subjects","journal-title":"J. Alzheimer's Dis.","doi-asserted-by":null},{"DOI":null,"key":"B4","year":"2018","issue":null,"author":null,"volume":"79","first-page":"17r11772","unstructured":null,"article-title":"Meta-analysis of the prevalence of major depressive disorder among older adults with dementia","journal-title":"J. Clin. Psychiatry","doi-asserted-by":null},{"DOI":null,"key":"B5","year":"2020","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":"Programme grants for applied research","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(11)60830-1","key":"B6","year":"2011","issue":null,"author":null,"volume":"378","first-page":"403","unstructured":null,"article-title":"Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"B7","year":"2021","issue":null,"author":null,"volume":"2","first-page":"CD013306","unstructured":null,"article-title":"Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":null,"key":"B8","year":"2018","issue":null,"author":null,"volume":"64","first-page":"17","unstructured":null,"article-title":"Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline","journal-title":"Can. Fam. Physician","doi-asserted-by":null},{"DOI":"10.5770/cgj.21.307","key":"B9","year":"2018","issue":null,"author":null,"volume":"21","first-page":"269","unstructured":null,"article-title":"Interprovincial variation of psychotropic prescriptions dispensed to older Canadian adults","journal-title":"Can. Geriatr. J.","doi-asserted-by":"crossref"},{"DOI":"10.1176/ps.48.10.1289","key":"B10","year":"1997","issue":null,"author":null,"volume":"48","first-page":"1289","unstructured":null,"article-title":"The impact of OBRA-87 on psychotropic drug prescribing in skilled nursing facilities","journal-title":"Psychiatr. Serv.","doi-asserted-by":"crossref"},{"DOI":"10.1177/1471301218762856","key":"B11","year":"2019","issue":null,"author":null,"volume":"18","first-page":"2950","unstructured":null,"article-title":"Managing behavioural and psychological symptoms in community dwelling older people with dementia: 2. A systematic review of qualitative studies","journal-title":"Dementia","doi-asserted-by":"crossref"},{"DOI":"10.5694/j.1326-5377.2003.tb05169.x","key":"B12","year":"2003","issue":null,"author":null,"volume":"178","first-page":"231","unstructured":null,"article-title":"Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery","journal-title":"Med. J. Aust.","doi-asserted-by":"crossref"},{"DOI":"10.1159/000355912","key":"B13","year":"2013","issue":null,"author":null,"volume":"3","first-page":"386","unstructured":null,"article-title":"The effect of psychosocial support intervention on depression in patients with dementia and their family caregivers: an assessor-blinded randomized controlled trial","journal-title":"Dement. Geriatr. Cogn. Dis. Extra","doi-asserted-by":"crossref"},{"DOI":null,"key":"B14","year":"2020","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1002/gps.6129","key":"B15","year":"2024","issue":null,"author":null,"volume":"39","first-page":"e6129","unstructured":null,"article-title":"Non-pharmacological interventions in the management of dementia-related psychosis: a systematic review and meta-analysis","journal-title":"Int. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2013.12.174","key":"B16","year":"2014","issue":null,"author":null,"volume":"22","first-page":"1565","unstructured":null,"article-title":"Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind and placebo controlled study","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":null,"key":"B17","year":"2012","issue":null,"author":null,"volume":"3","first-page":"73","unstructured":null,"article-title":"Behavioral and psychological symptoms of dementia","journal-title":"Front. Neurol.","doi-asserted-by":null},{"DOI":"10.3233/JAD-200507","key":"B18","year":"2020","issue":null,"author":null,"volume":"78","first-page":"711","unstructured":null,"article-title":"Differences in clinical presentation of behavioral and psychological symptoms of dementia in Alzheimer's disease according to sex and education level","journal-title":"J. Alzheimer's Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1097/WAD.0000000000000302","key":"B19","year":"2019","issue":null,"author":null,"volume":"33","first-page":"154","unstructured":null,"article-title":"Identification of sexual disinhibition in dementia by family caregivers","journal-title":"Alzheimer Dis. Assoc. Disord.","doi-asserted-by":"crossref"},{"DOI":"10.1177/0145445514561317","key":"B20","year":"2015","issue":null,"author":null,"volume":"39","first-page":"390","unstructured":null,"article-title":"Cognitive behavior therapy for anxiety in people with dementia: a clinician guideline for a person-centered approach","journal-title":"Behav. Modif.","doi-asserted-by":"crossref"},{"DOI":"10.1177/07334648211047347","key":"B21","year":"2022","issue":null,"author":null,"volume":"41","first-page":"600","unstructured":null,"article-title":"Telehealth use among older adults during COVID-19: associations with sociodemographic and health characteristics, technology device ownership, and technology learning","journal-title":"J. Appl. Gerontol.","doi-asserted-by":"crossref"},{"DOI":"10.1093/geronj/44.3.M77","key":"B22","year":"1989","issue":null,"author":null,"volume":"44","first-page":"M77","unstructured":null,"article-title":"A description of agitation in a nursing home","journal-title":"J. Gerontol.","doi-asserted-by":"crossref"},{"DOI":"10.1002/alz.70224","key":"B23","year":"2025","issue":null,"author":null,"volume":"21","first-page":"e70224","unstructured":null,"article-title":"Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":"10.1017/S1041610214001963","key":"B24","year":"2015","issue":null,"author":null,"volume":"27","first-page":"7","unstructured":null,"article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","journal-title":"Int. Psychogeriatr.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2020.09.002","key":"B25","year":"2020","issue":null,"author":null,"volume":"28","first-page":"1256","unstructured":null,"article-title":"Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1017/S104161022200103X","key":"B26","year":"2024","issue":null,"author":null,"volume":"36","first-page":"251","unstructured":null,"article-title":"Reduction and prevention of agitation in persons with neurocognitive disorders: an International Psychogeriatric Association consensus algorithm","journal-title":"Int. Psychogeriatr.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B27","year":"1997","issue":null,"author":null,"volume":"48","first-page":"S10","unstructured":null,"article-title":"The Neuropsychiatry Inventory: assessing psychopathology in dementia patients","journal-title":"Neurology","doi-asserted-by":null},{"DOI":"10.1212/WNL.44.12.2308","key":"B28","year":"1994","issue":null,"author":null,"volume":"44","first-page":"2308","unstructured":null,"article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","journal-title":"Neurology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaneurol.2023.1835","key":"B29","year":"2023","issue":null,"author":null,"volume":"80","first-page":"813","unstructured":null,"article-title":"Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-analysis","journal-title":"JAMA Neurol","doi-asserted-by":"crossref"},{"DOI":"10.1002/alz.12335","key":"B30","year":"2021","issue":null,"author":null,"volume":"17","first-page":"1687","unstructured":null,"article-title":"Agitation in Alzheimer's disease: novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":"10.1097/WAD.0b013e31822c5bb3","key":"B31","year":"2012","issue":null,"author":null,"volume":"26","first-page":"119","unstructured":null,"article-title":"Three-week nutritional supplementation effect on long-term nutritional status of patients with mild Alzheimer disease","journal-title":"Alzheimer Dis. Assoc. Disord.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s41669-023-00440-z","key":"B32","year":"2023","issue":null,"author":null,"volume":"7","first-page":"887","unstructured":null,"article-title":"Cost-effectiveness of non-pharmacological interventions for mild cognitive impairment and dementia: a systematic review of economic evaluations and a review of reviews","journal-title":"Pharmacoecon. Open","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13195-022-00991-z","key":"B33","year":"2022","issue":null,"author":null,"volume":"14","first-page":"48","unstructured":null,"article-title":"Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis","journal-title":"Alzheimer's Res. Ther.","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa041470","key":"B34","year":"2004","issue":null,"author":null,"volume":"351","first-page":"2509","unstructured":null,"article-title":"Rivastigmine for dementia associated with Parkinson's disease","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40266-018-0546-2","key":"B35","year":"2018","issue":null,"author":null,"volume":"35","first-page":"545","unstructured":null,"article-title":"Efficacy and safety of analgesic treatment for depression in people with advanced dementia: randomised, multicentre, double-blind, placebo-controlled trial (DEP.PAIN.DEM)","journal-title":"Drugs Aging","doi-asserted-by":"crossref"},{"DOI":"10.1097/WAD.0b013e3182087dbc","key":"B36","year":"2011","issue":null,"author":null,"volume":"25","first-page":"213","unstructured":null,"article-title":"The efficacy of nonpharmacological treatment for dementia-related apathy","journal-title":"Alzheimer Dis. Assoc. Disord.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B37","year":"1996","issue":null,"author":null,"volume":"8","first-page":"497","unstructured":null,"article-title":"Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment","journal-title":"Int. Psychogeriatr.","doi-asserted-by":null},{"DOI":"10.1080/07317115.2014.988900","key":"B38","year":"2015","issue":null,"author":null,"volume":"38","first-page":"179","unstructured":null,"article-title":"Ethnicity is an inherent criterion for assessment of individualized music for persons with Alzheimer's disease","journal-title":"Clin. Gerontol.","doi-asserted-by":"crossref"},{"DOI":"10.7326/0003-4819-146-11-200706050-00006","key":"B39","year":"2007","issue":null,"author":null,"volume":"146","first-page":"775","unstructured":null,"article-title":"Antipsychotic drug use and mortality in older adults with dementia","journal-title":"Ann. Intern. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.38330.470486.8F","key":"B40","year":"2005","issue":null,"author":null,"volume":"330","first-page":"445","unstructured":null,"article-title":"Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1093/geront/gnz140","key":"B41","year":"2020","issue":null,"author":null,"volume":"60","first-page":"896","unstructured":null,"article-title":"Nomenclature used by family caregivers to describe and characterize neuropsychiatric symptoms","journal-title":"Gerontologist","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2012.36918","key":"B42","year":"2012","issue":null,"author":null,"volume":"308","first-page":"2020","unstructured":null,"article-title":"Nonpharmacologic management of behavioral symptoms in dementia","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1093/geront/gnp087","key":"B43","year":"2009","issue":null,"author":null,"volume":"49","first-page":"428","unstructured":null,"article-title":"The Tailored Activity Program to reduce behavioral symptoms in individuals with dementia: feasibility, acceptability, and replication potential","journal-title":"Gerontologist","doi-asserted-by":"crossref"},{"DOI":null,"key":"B44","year":"2019","issue":null,"author":null,"volume":"11","first-page":"340","unstructured":null,"article-title":"Detection of anxiety symptoms in persons with dementia: a systematic review","journal-title":"Alzheimer's Dement.","doi-asserted-by":null},{"DOI":null,"key":"B45","year":"2021","issue":null,"author":null,"volume":"13","first-page":"e12169","unstructured":null,"article-title":"Prevalent, persistent, and impairing: longitudinal course and impact of apathy in Alzheimer's disease","journal-title":"Alzheimer's Dement. Diagn. Assess. Dis. Monit.","doi-asserted-by":null},{"DOI":null,"key":"B46","year":"2016","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.5770/cgj.28.820","key":"B47","year":"2025","issue":null,"author":null,"volume":"28","first-page":"91","unstructured":null,"article-title":"The Canadian Coalition for Seniors' Mental Health Canadian clinical practice guidelines for assessing and managing behavioural and psychological symptoms of dementia (BPSD)","journal-title":"Can. Geriatr. J.","doi-asserted-by":"crossref"},{"DOI":"10.1002/alz.12035","key":"B48","year":"2020","issue":null,"author":null,"volume":"16","first-page":"541","unstructured":null,"article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":"10.1186/alzrt201","key":"B49","year":"2013","issue":null,"author":null,"volume":"5","first-page":"S5","unstructured":null,"article-title":"Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012","journal-title":"Alzheimer's Res. Ther.","doi-asserted-by":"crossref"},{"DOI":"10.1177/0269881117714047","key":"B50","year":"2017","issue":null,"author":null,"volume":"31","first-page":"1544","unstructured":null,"article-title":"Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies","journal-title":"J. Psychopharmacol.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.arr.2022.101568","key":"B51","year":"2022","issue":null,"author":null,"volume":"75","first-page":"101568","unstructured":null,"article-title":"Pharmacological treatments for psychotic symptoms in dementia: a systematic review with pairwise and network meta-analysis","journal-title":"Ageing Res. Rev.","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.d4065","key":"B52","year":"2011","issue":null,"author":null,"volume":"343","first-page":"d4065","unstructured":null,"article-title":"Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.3109/15622975.2010.538083","key":"B53","year":"2011","issue":null,"author":null,"volume":"12","first-page":"2","unstructured":null,"article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias","journal-title":"World J. Biol. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1002/alz.12105","key":"B54","year":"2020","issue":null,"author":null,"volume":"16","first-page":"1182","unstructured":null,"article-title":"Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jns.2008.03.023","key":"B55","year":"2008","issue":null,"author":null,"volume":"271","first-page":"97","unstructured":null,"article-title":"A functional neuroimaging study of appetite loss in Alzheimer's disease","journal-title":"J. Neurol. Sci.","doi-asserted-by":"crossref"},{"DOI":"10.1097/JCP.0000000000000710","key":"B56","year":"2017","issue":null,"author":null,"volume":"37","first-page":"347","unstructured":null,"article-title":"Aripiprazole once-monthly in the treatment of acute psychotic episodes in schizophrenia: post hoc analysis of Positive and Negative Syndrome Scale Marder factor scores","journal-title":"J. Clin. Psychopharmacol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B57","year":"2017","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/jgs.15541","key":"B58","year":"2018","issue":null,"author":null,"volume":"66","first-page":"2120","unstructured":null,"article-title":"Personalized goal attainment in dementia care: measuring what persons with dementia and their caregivers want","journal-title":"J. Am. Geriatr. Soc.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2022.12.286","key":"B59","year":"2023","issue":null,"author":null,"volume":"31","first-page":"S10","unstructured":null,"article-title":"Social determinants of health in dementia","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.h369","key":"B60","year":"2015","issue":null,"author":null,"volume":"350","first-page":"h369","unstructured":null,"article-title":"Assessment and management of behavioral and psychological symptoms of dementia","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":null,"key":"B61","year":"2011","issue":null,"author":null,"volume":"68","first-page":"190","unstructured":null,"article-title":"Trends in antipsychotic use in dementia 1999–2007","journal-title":"JAMA","doi-asserted-by":null},{"DOI":"10.3233/JAD-150200","key":"B62","year":"2015","issue":null,"author":null,"volume":"48","first-page":"453","unstructured":null,"article-title":"Depression and suicidal ideation during two psychosocial treatments in older adults with major depression and dementia","journal-title":"J. Alzheimer's Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1017/S0144686X0000502X","key":"B63","year":"1992","issue":null,"author":null,"volume":"12","first-page":"269","unstructured":null,"article-title":"Towards a theory of dementia care: personhood and well-being","journal-title":"Ageing Soc","doi-asserted-by":"crossref"},{"DOI":"10.1017/S1041610213002019","key":"B64","year":"2014","issue":null,"author":null,"volume":"26","first-page":"363","unstructured":null,"article-title":"Variability between nursing homes in prevalence of antipsychotic use in patients with dementia","journal-title":"Int. Psychogeriatr.","doi-asserted-by":"crossref"},{"DOI":"10.1002/(SICI)1099-1166(199602)11:2<97::AID-GPS310>3.0.CO;2-W","key":"B65","year":"1996","issue":null,"author":null,"volume":"11","first-page":"97","unstructured":null,"article-title":"Cognitive therapy for depression in the elderly","journal-title":"Int. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.trci.2017.07.001","key":"B66","year":"2017","issue":null,"author":null,"volume":"3","first-page":"440","unstructured":null,"article-title":"Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":"10.1111/jgs.19489","key":"B67","year":"2025","issue":null,"author":null,"volume":"73","first-page":"2589","unstructured":null,"article-title":"Treatment of inappropriate sexual behavior in persons with dementia: a systematic review","journal-title":"J. Am. Geriatr. Soc.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ctim.2018.04.013","key":"B68","year":"2018","issue":null,"author":null,"volume":"38","first-page":"74","unstructured":null,"article-title":"Shiatsu as an adjuvant therapy for depression in patients with Alzheimer's disease: a pilot study","journal-title":"Complement. Ther. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaneurol.2023.3810","key":"B69","year":"2023","issue":null,"author":null,"volume":"80","first-page":"1307","unstructured":null,"article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","journal-title":"JAMA Neurol","doi-asserted-by":"crossref"},{"DOI":"10.1176/appi.ajp.2016.15020248","key":"B70","year":"2016","issue":null,"author":null,"volume":"173","first-page":"473","unstructured":null,"article-title":"Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD study","journal-title":"Am. J. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2017.05.015","key":"B71","year":"2018","issue":null,"author":null,"volume":"26","first-page":"25","unstructured":null,"article-title":"Targeted interdisciplinary model for evaluation and treatment of neuropsychiatric symptoms: a cluster randomized controlled trial","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1002/alz.14522","key":"B72","year":"2025","issue":null,"author":null,"volume":"21","first-page":"e14522","unstructured":null,"article-title":"Optimizing mealtime care and outcomes for people with dementia and their caregivers: a systematic review and meta-analysis of intervention studies","journal-title":"Alzheimer's Dement","doi-asserted-by":"crossref"},{"DOI":null,"key":"B73","year":"2014","issue":null,"author":null,"volume":"18","first-page":"1","unstructured":null,"article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia","journal-title":"Health Technol. Assess.","doi-asserted-by":null},{"DOI":"10.1176/jnp.15.1.67","key":"B74","year":"2003","issue":null,"author":null,"volume":"15","first-page":"67","unstructured":null,"article-title":"Patterns of change in the treatment of psychiatric symptoms in patients with probable Alzheimer's disease from 1983 to 2000","journal-title":"J. Neuropsychiatry Clin. Neurosci.","doi-asserted-by":"crossref"},{"DOI":"10.1001/archpsyc.60.7.737","key":"B75","year":"2003","issue":null,"author":null,"volume":"60","first-page":"737","unstructured":null,"article-title":"Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS","journal-title":"Arch. Gen. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.288.12.1475","key":"B76","year":"2002","issue":null,"author":null,"volume":"288","first-page":"1475","unstructured":null,"article-title":"Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the Cardiovascular Health Study","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2017.08.014","key":"B77","year":"2017","issue":null,"author":null,"volume":"25","first-page":"1326","unstructured":null,"article-title":"Association between antidepressants and fall-related injuries among long-term care residents","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1097/00019442-200002000-00009","key":"B78","year":"2000","issue":null,"author":null,"volume":"8","first-page":"66","unstructured":null,"article-title":"A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2019.07.014","key":"B79","year":"2020","issue":null,"author":null,"volume":"28","first-page":"410","unstructured":null,"article-title":"Recommendations for the nonpharmacological treatment of apathy in brain disorders","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamapsychiatry.2014.3018","key":"B80","year":"2015","issue":null,"author":null,"volume":"72","first-page":"438","unstructured":null,"article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","journal-title":"JAMA Psychiatry","doi-asserted-by":"crossref"},{"DOI":null,"key":"B81","year":"2020","issue":null,"author":null,"volume":"11","first-page":"CD009178","unstructured":null,"article-title":"Pharmacotherapies for sleep disturbances in dementia","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":"10.1093/ageing/afaf014","key":"B82","year":"2025","issue":null,"author":null,"volume":"54","first-page":"afaf014","unstructured":null,"article-title":"Deprescribing in cognitively vulnerable older people: development and validation of STOPPCog criteria","journal-title":"Age Ageing","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(00)03399-7","key":"B83","year":"2000","issue":null,"author":null,"volume":"356","first-page":"2031","unstructured":null,"article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"B84","year":"2019","issue":null,"author":null,"volume":"3","first-page":"CD003154","unstructured":null,"article-title":"Memantine for dementia","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":"10.1002/gps.3762","key":"B85","year":"2012","issue":null,"author":null,"volume":"27","first-page":"1163","unstructured":null,"article-title":"Specialist mental health consultation for depression in Australian aged care residents with dementia: a cluster randomized trial","journal-title":"Int. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1002/alz.12358","key":"B86","year":"2021","issue":null,"author":null,"volume":"17","first-page":"1892","unstructured":null,"article-title":"Diagnostic criteria for apathy in neurocognitive disorders","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamaneurol.2021.3356","key":"B87","year":"2021","issue":null,"author":null,"volume":"78","first-page":"1324","unstructured":null,"article-title":"Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial","journal-title":"JAMA Neurol","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj-2023-076268","key":"B88","year":"2024","issue":null,"author":null,"volume":"385","first-page":"e076268","unstructured":null,"article-title":"Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jpainsymman.2020.08.034","key":"B89","year":"2021","issue":null,"author":null,"volume":"61","first-page":"438","unstructured":null,"article-title":"Racial/ethnic differences in staff-assessed pain behaviors among newly admitted nursing home residents","journal-title":"J. Pain Symptom Manag.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B90","year":"2016","issue":null,"author":null,"volume":"8","first-page":"1","unstructured":null,"article-title":"Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial","journal-title":"Open Access J. Clin. Trials","doi-asserted-by":null},{"DOI":"10.1002/alz.14282","key":"B91","year":"2024","issue":null,"author":null,"volume":"20","first-page":"8002","unstructured":null,"article-title":"Brexpiprazole treatment for agitation in Alzheimer's dementia: a randomized study","journal-title":"Alzheimer's Dement.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B92","year":"2019","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/s40478-023-01576-z","key":"B93","year":"2023","issue":null,"author":null,"volume":"11","first-page":"89","unstructured":null,"article-title":"Neurodegenerative pathologies associated with behavioral and psychological symptoms of dementia in a community-based autopsy cohort","journal-title":"Acta Neuropathol. Commun.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B94","year":"2018","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.neubiorev.2023.105507","key":"B95","year":"2024","issue":null,"author":null,"volume":"157","first-page":"105507","unstructured":null,"article-title":"Clinical effectiveness of pharmacological and non-pharmacological treatments for the management of anxiety in community dwelling people living with dementia: a systematic review and meta-analysis","journal-title":"Neurosci. Biobehav. Rev.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B96","year":"2017","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jagp.2025.06.016","key":"B97","year":"2025","issue":null,"author":null,"volume":"33","first-page":"1331","unstructured":null,"article-title":"The impact of nondepressive neuropsychiatric symptoms on mortality in dementia: a systematic review and meta-analysis","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1097/00019442-200203000-00003","key":"B98","year":"2002","issue":null,"author":null,"volume":"10","first-page":"125","unstructured":null,"article-title":"Provisional diagnostic criteria for depression of Alzheimer disease","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1111/imj.13215","key":"B99","year":"2016","issue":null,"author":null,"volume":"46","first-page":"1189","unstructured":null,"article-title":"Medication appropriateness tool for co-morbid health conditions in dementia: consensus recommendations from a multidisciplinary expert panel","journal-title":"Intern. Med. J.","doi-asserted-by":"crossref"},{"DOI":"10.1111/hex.70289","key":"B100","year":"2025","issue":null,"author":null,"volume":"28","first-page":"e70289","unstructured":null,"article-title":"Reimagining dementia care: a complex intervention systematic review on optimising social prescribing (SP) for people living with dementia (PLWD) in the United Kingdom","journal-title":"Health Expectations","doi-asserted-by":"crossref"},{"DOI":null,"key":"B101","year":"2021","issue":null,"author":null,"volume":"2","first-page":"CD009081","unstructured":null,"article-title":"Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":"10.1001/jama.2014.93","key":"B102","year":"2014","issue":null,"author":null,"volume":"311","first-page":"682","unstructured":null,"article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":null,"key":"B103","year":"2014","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1038/s41591-025-03569-y","key":"B104","year":"2025","issue":null,"author":null,"volume":"31","first-page":"1586","unstructured":null,"article-title":"Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial","journal-title":"Nat. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jamda.2016.04.006","key":"B105","year":"2016","issue":null,"author":null,"volume":"17","first-page":"741","unstructured":null,"article-title":"Apathy and its response to antipsychotic review and nonpharmacological interventions in people with dementia living in nursing homes: WHELD, a factorial cluster randomized controlled trial","journal-title":"J. Am. Med. Dir. Assoc.","doi-asserted-by":"crossref"},{"DOI":"10.5694/mja2.50015","key":"B106","year":"2019","issue":null,"author":null,"volume":"210","first-page":"174","unstructured":null,"article-title":"Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary","journal-title":"Med. J. Aust.","doi-asserted-by":"crossref"},{"DOI":"10.1080/08952841.2020.1735925","key":"B107","year":"2021","issue":null,"author":null,"volume":"33","first-page":"635","unstructured":null,"article-title":"Gender differences in presentation and management of behavioral and psychological symptoms associated with dementia among nursing home residents with moderate to severe dementia","journal-title":"J. Women Aging","doi-asserted-by":"crossref"},{"DOI":"10.1176/appi.ajp.2015.173501","key":"B108","year":"2016","issue":null,"author":null,"volume":"173","first-page":"543","unstructured":null,"article-title":"The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia","journal-title":"Am. J. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12877-017-0636-8","key":"B109","year":"2017","issue":null,"author":null,"volume":"17","first-page":"244","unstructured":null,"article-title":"Antipsychotics and dementia in Canada: a retrospective cross-sectional study of four health sectors","journal-title":"BMC Geriatr","doi-asserted-by":"crossref"},{"DOI":"10.1111/jgs.12061","key":"B110","year":"2013","issue":null,"author":null,"volume":"61","first-page":"55","unstructured":null,"article-title":"Older men with dementia are at greater risk than women of serious events after initiating antipsychotic therapy","journal-title":"J. Am. Geriatr. Soc.","doi-asserted-by":"crossref"},{"DOI":"10.1159/000354366","key":"B111","year":"2013","issue":null,"author":null,"volume":"36","first-page":"340","unstructured":null,"article-title":"The effect of person-centred dementia care to prevent agitation and other neuropsychiatric symptoms and enhance quality of life in nursing home patients: a 10-month randomized controlled trial","journal-title":"Dement. Geriatr. Cogn. Disord.","doi-asserted-by":"crossref"},{"DOI":"10.1097/JGP.0b013e3181c796eb","key":"B112","year":"2010","issue":null,"author":null,"volume":"18","first-page":"136","unstructured":null,"article-title":"Sertraline for the treatment of depression in Alzheimer disease","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.4088/JCP.12m08099","key":"B113","year":"2013","issue":null,"author":null,"volume":"74","first-page":"810","unstructured":null,"article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial","journal-title":"J. Clin. Psychiatry","doi-asserted-by":"crossref"},{"DOI":null,"key":"B114","year":"2018","issue":null,"author":null,"volume":"5","first-page":"CD012197","unstructured":null,"article-title":"Pharmacological interventions for apathy in Alzheimer's disease","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":"10.1016/j.jamda.2016.09.019","key":"B115","year":"2017","issue":null,"author":null,"volume":"18","first-page":"87.e15","unstructured":null,"article-title":"Risk of hip fracture in benzodiazepine users with and without Alzheimer disease","journal-title":"J. Am. Med. Dir. Assoc.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2024.25845","key":"B116","year":"2025","issue":null,"author":null,"volume":"333","first-page":"962","unstructured":null,"article-title":"Palliative care program for community-dwelling individuals with dementia and caregivers: the IN-PEACE randomized clinical trial","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.14283/jpad.2018.15","key":"B117","year":"2018","issue":null,"author":null,"volume":"5","first-page":"98","unstructured":null,"article-title":"Identifying better outcome measures to improve treatment of agitation in dementia: a report from the EU/US/CTAD Task Force","journal-title":"J. Prev. Alzheimer's Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1024/1661-8157/a001547","key":"B118","year":"2014","issue":null,"author":null,"volume":"103","first-page":"135","unstructured":null,"article-title":"Recommendations for the diagnosis and treatment of behavioral and psychological symptoms of dementia (BPSD)","journal-title":"Praxis","doi-asserted-by":"crossref"},{"DOI":"10.1017/cjn.2016.426","key":"B119","year":"2017","issue":null,"author":null,"volume":"44","first-page":"267","unstructured":null,"article-title":"Pharmacological therapy for apathy in Alzheimer's disease: a systematic review and meta-analysis","journal-title":"Can. J. Neurol. Sci.","doi-asserted-by":"crossref"},{"DOI":"10.1093/geront/gnx083","key":"B120","year":"2018","issue":null,"author":null,"volume":"58","first-page":"e239","unstructured":null,"article-title":"Reducing antipsychotic medication use in nursing homes: a qualitative study of nursing staff perceptions","journal-title":"Gerontologist","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2023.13239","key":"B121","year":"2023","issue":null,"author":null,"volume":"330","first-page":"512","unstructured":null,"article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1468-1331.2012.03784.x","key":"B122","year":"2012","issue":null,"author":null,"volume":"19","first-page":"1159","unstructured":null,"article-title":"EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia","journal-title":"Eur. J. Neurol.","doi-asserted-by":"crossref"},{"DOI":"10.1136/jnnp-2016-313660","key":"B123","year":"2016","issue":null,"author":null,"volume":"87","first-page":"1368","unstructured":null,"article-title":"Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis","journal-title":"J. Neurol. Neurosurg. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1192/bjp.bp.113.140087","key":"B124","year":"2015","issue":null,"author":null,"volume":"206","first-page":"509","unstructured":null,"article-title":"Cognitive-behavioural therapy for anxiety in dementia: pilot randomised controlled trial","journal-title":"Br. J. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jagp.2013.01.007","key":"B125","year":"2013","issue":null,"author":null,"volume":"21","first-page":"696","unstructured":null,"article-title":"The Peaceful Mind program: a pilot test of a cognitive-behavioral therapy-based intervention for anxious patients with dementia","journal-title":"Am. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1002/gps.1858","key":"B126","year":"2008","issue":null,"author":null,"volume":"23","first-page":"170","unstructured":null,"article-title":"Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study","journal-title":"Int. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1177/0091270011405665","key":"B127","year":"2012","issue":null,"author":null,"volume":"52","first-page":"947","unstructured":null,"article-title":"New insights: dose-response relationship between psychotropic drugs and falls: a study in nursing home residents with dementia","journal-title":"J. Clin. Pharmacol.","doi-asserted-by":"crossref"},{"DOI":"10.1503/cmaj.160126","key":"B128","year":"2017","issue":null,"author":null,"volume":"189","first-page":"E519","unstructured":null,"article-title":"Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease","journal-title":"CMAJ","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2034634","key":"B129","year":"2021","issue":null,"author":null,"volume":"385","first-page":"309","unstructured":null,"article-title":"Trial of pimavanserin in dementia-related psychosis","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1093/geronb/52B.4.P159","key":"B130","year":"1997","issue":null,"author":null,"volume":"52B","first-page":"159","unstructured":null,"article-title":"Behavioral treatment of depression in dementia patients: a controlled clinical trial","journal-title":"J. Gerontol.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jamda.2014.06.012","key":"B131","year":"2014","issue":null,"author":null,"volume":"15","first-page":"706","unstructured":null,"article-title":"Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review","journal-title":"J. Am. Med. Dir. Assoc.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eurpsy.2014.02.004","key":"B132","year":"2015","issue":null,"author":null,"volume":"30","first-page":"251","unstructured":null,"article-title":"Apathy in nursing home residents with dementia: results from a cluster-randomized controlled trial","journal-title":"Eur. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.289.2.210","key":"B133","year":"2003","issue":null,"author":null,"volume":"289","first-page":"210","unstructured":null,"article-title":"Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2212948","key":"B134","year":"2023","issue":null,"author":null,"volume":"388","first-page":"9","unstructured":null,"article-title":"Lecanemab in early Alzheimer's disease","journal-title":"N. Engl. J. Med.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B135","year":"2018","issue":null,"author":null,"volume":"3","first-page":"CD007726","unstructured":null,"article-title":"Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":null,"key":"B136","year":"2023","issue":null,"author":null,"volume":"15","first-page":"e12398","unstructured":null,"article-title":"A data-driven examination of apathy and depressive symptoms in dementia with independent replication","journal-title":"Alzheimer's Dement.","doi-asserted-by":null},{"DOI":"10.1017/S0033291704003897","key":"B137","year":"2005","issue":null,"author":null,"volume":"35","first-page":"307","unstructured":null,"article-title":"Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies","journal-title":"Psychol. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1002/gps.2586","key":"B138","year":"2011","issue":null,"author":null,"volume":"26","first-page":"723","unstructured":null,"article-title":"The effects of a nursing guideline on depression in psychogeriatric nursing home residents with dementia","journal-title":"Int. J. Geriatr. Psychiatry","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clnu.2015.09.004","key":"B139","year":"2015","issue":null,"author":null,"volume":"34","first-page":"1052","unstructured":null,"article-title":"ESPEN guidelines on nutrition in dementia","journal-title":"Clin. Nutr.","doi-asserted-by":"crossref"},{"DOI":null,"key":"B140","year":"2021","issue":null,"author":null,"volume":"374","first-page":"n1925","unstructured":null,"article-title":"Use of antipsychotic drugs and cholinesterase inhibitors and risk of falls and fractures: self-controlled case series","journal-title":"BMJ","doi-asserted-by":null},{"DOI":"10.1093/ageing/afab218","key":"B141","year":"2022a","issue":null,"author":null,"volume":"51","first-page":"afab218","unstructured":null,"article-title":"Barriers and facilitators to virtual care in a geriatric medicine clinic: a semi-structured interview study of patient, caregiver and healthcare provider perspectives","journal-title":"Age Ageing","doi-asserted-by":"crossref"},{"DOI":"10.1503/cmaj.180551","key":"B142","year":"2018","issue":null,"author":null,"volume":"190","first-page":"E1376","unstructured":null,"article-title":"Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study","journal-title":"CMAJ","doi-asserted-by":"crossref"},{"DOI":"10.7326/M19-0993","key":"B143","year":"2019","issue":null,"author":null,"volume":"171","first-page":"633","unstructured":null,"article-title":"Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis","journal-title":"Ann. Intern. Med.","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12877-020-01607-7","key":"B144","year":"2020","issue":null,"author":null,"volume":"20","first-page":"212","unstructured":null,"article-title":"Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis","journal-title":"BMC Geriatr","doi-asserted-by":"crossref"},{"DOI":null,"key":"B145","year":"2021","issue":null,"author":null,"volume":"372","first-page":"n532","unstructured":null,"article-title":"Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis","journal-title":"BMJ","doi-asserted-by":null},{"DOI":"10.1016/j.jamda.2024.03.007","key":"B146","year":"2024","issue":null,"author":null,"volume":"25","first-page":"837","unstructured":null,"article-title":"Guideline recommendations on behavioral and psychological symptoms of dementia: a systematic review","journal-title":"J. Am. Med. Dir. Assoc.","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj-2021-069187","key":"B147","year":"2022b","issue":null,"author":null,"volume":"376","first-page":"e069187","unstructured":null,"article-title":"Managing neuropsychiatric symptoms in patients with dementia","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":null,"key":"B148","year":"2015","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"B149","year":"2023","issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":"Non-pharmacological interventions for sleep disturbances in people with dementia","journal-title":"Cochrane Database Syst. Rev.","doi-asserted-by":null},{"DOI":"10.1093/ageing/afac047","key":"B150","year":"2022","issue":null,"author":null,"volume":"51","first-page":"afac047","unstructured":null,"article-title":"Family carer perspectives on the language of behaviour change in dementia: an online mixed methods survey","journal-title":"Age Ageing","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2019.0828","key":"B151","year":"2019","issue":null,"author":null,"volume":"2","first-page":"e190828","unstructured":null,"article-title":"Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis","journal-title":"JAMA Netw. Open","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jamda.2023.01.014","key":"B152","year":"2023","issue":null,"author":null,"volume":"24","first-page":"555","unstructured":null,"article-title":"State variation in antipsychotic use among assisted living residents with dementia","journal-title":"J. Am. Med. Dir. Assoc.","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5,7]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Annual Review of Clinical Psychology"],"published-print":{"date-parts":[[2026,5,7]]},"reference-count":152,"published-online":null,"references-count":152,"short-container-title":[],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1146/annurev-clinpsy-061724-085912","is_oa":false,"title":"Management of Behavioral and Psychological Symptoms of Dementia: Nonpharmacologic and Pharmacologic Interventions","updated":"2026-02-13T15:49:00+00:00","published_date":"2026-02-12","best_oa_location":null}},"created_at":"2026-05-12T13:18:16.305Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"category","value":"Psychology, Clinical","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"condition","value":"Behavioral and Psychological Symptoms of Dementia","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"condition","value":"Dementia with Lewy Bodies","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"condition","value":"Mild Cognitive Impairment","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"aripiprazole","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"citalopram","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"donepezil","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"galantamine","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"memantine","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"olanzapine","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"quetiapine","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"risperidone","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"generic","value":"rivastigmine","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"modality","value":"Acetylcholinesterase Inhibitor","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"modality","value":"Atypical Antipsychotic","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"modality","value":"NMDA Receptor Antagonist","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"modality","value":"Nonpharmacological Intervention","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"modality","value":"Selective Serotonin Reuptake Inhibitor","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"warning","value":"Mortality risk data for antipsychotics (OR 1.54) is from a 2005 meta-analysis cited within the guideline; more recent estimates may differ.","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"warning","value":"No sample size tag was applied as this is a guideline synthesis, not a single primary study with a defined N.","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"warning","value":"The full text extracted is the 2016 Australian NHMRC Clinical Practice Guideline, not the 2026 Annual Review of Clinical Psychology article referenced in the DOI metadata — these appear to be two different documents. The summary reflects the guideline content as extracted.","value_numeric":null},{"paper_doi":"10.1146/annurev-clinpsy-061724-085912","tag_type":"warning","value":"The guideline was approved in February 2016 with a 5-year validity window; it may be substantially outdated relative to current evidence as of 2026.","value_numeric":null}],"summaries":{"what_studied":"This is an Australian national clinical practice guideline (adapted from the UK NICE guideline via the ADAPTE process) covering the diagnosis and management of dementia across community, residential, and hospital settings. It addresses assessment, pharmacological and nonpharmacological BPSD management, carer support, and palliative care, with evidence graded using GRADE methodology.","key_result":"Nonpharmacological approaches (multicomponent, music, massage, reminiscence, behavioral management) are recommended first-line for BPSD. Antipsychotics should generally be avoided in mild-to-moderate BPSD due to increased risk of cerebrovascular events and death (3.5% vs 2.3% placebo mortality in meta-analysis of 15 trials; OR 1.54). SSRIs — especially citalopram — showed significant benefit for agitation in two large RCTs. AChEIs showed small but significant benefits on cognition and ADL in mild-to-severe Alzheimer's disease and other dementia subtypes.","limitations":"Evidence base is largely low-to-very-low GRADE quality for nonpharmacological interventions. The guideline was adapted for Australia in 2016 from a 2006 UK source and may not reflect current evidence. Few economic evaluations were conducted in Australian settings.","practice_takeaway":"Try nonpharmacological strategies first for BPSD — music, massage, behavioral management, and multicomponent programs have the best evidence. Reserve antipsychotics for severe psychosis or agitation causing significant distress, use the lowest effective dose, reassess every 4–12 weeks, and actively deprescribe when possible."}},{"doi":"10.1212/wnl.0000000000214343","pmid":"41406402","title":"High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia","journal_title":"Neurology","journal_issn":"0028-3878","published_at":"2025-12-17T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12720290/","source_score":2142,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-12-20","doi":"10.1212/wnl.0000000000214343","days":"30","issn":"0028-3878","rank":"1","field":"Clinical Medicine","score":"2142","category":"Clinical Neurology","categories":["Clinical Neurology"],"_categories":["Clinical Neurology"]},"pubmed":{"doi":"10.1212/WNL.0000000000214343","title":"High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia: Evidence From a 25-Year Prospective Cohort Study.","journal":"Neurology","methods":"","results":"This study included 27,670 participants (mean baseline age 58.1 years, SD 7.6; 61% female). During a median of 25 years of follow-up, 3,208 incident dementia cases were recorded. Consumption of ≥50 g/d of high-fat cheese (>20% fat) was associated with a reduced risk of all-cause dementia (HR 0.87; 95% CI, 0.78-0.97) and VaD (HR 0.71, 95% CI 0.52-0.96) compared with lower intake (<15 g/d). An inverse association between high-fat cheese and AD was found among ","abstract":"$32","keywords":[],"pubmed_id":"41406402","conclusions":"","publication_date":"2025-12-17T00:00:00"},"crossref":{"DOI":"10.1212/wnl.0000000000214343","URL":"https://doi.org/10.1212/wnl.0000000000214343","ISSN":["0028-3878","1526-632X"],"link":[{"URL":"https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000214343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"2","score":1,"title":["High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia"],"author":[{"given":"Yufeng","family":"Du","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Lanzhou University, Gansu, China;"},{"name":"Nutritional Epidemiology, Department of Clinical Sciences Malmö, Lund University, Sweden;"}]},{"given":"Yan","family":"Borné","sequence":"additional","affiliation":[{"name":"Nutritional Epidemiology, Department of Clinical Sciences Malmö, Lund University, Sweden;"}]},{"given":"Jessica","family":"Samuelsson","sequence":"additional","affiliation":[{"name":"Nutritional Epidemiology, Department of Clinical Sciences Malmö, Lund University, Sweden;"},{"name":"Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health at the University of Gothenburg, Mölndal, Sweden;"}]},{"given":"Isabelle","family":"Glans","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden;"},{"name":"Memory Clinic, Skåne University Hospital, Malmö, Sweden;"}]},{"given":"Xiaobin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Lanzhou University, Gansu, China;"}]},{"given":"Katarina","family":"Nägga","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden;"},{"name":"Department of Geriatrics and Palliative Medicine, and Department of Health, Medicine and Caring Sciences, Linköping University, Sweden; and"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden;"},{"name":"Memory Clinic, Skåne University Hospital, Malmö, Sweden;"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden;"}]},{"given":"Emily","family":"Sonestedt","sequence":"additional","affiliation":[{"name":"Nutritional Epidemiology, Department of Clinical Sciences Malmö, Lund University, Sweden;"},{"name":"Department of Food and Meal Science and the Research Environment MEAL, Faculty of Natural Science, Kristianstad University, Sweden."}]}],"issued":{"date-parts":[[2026,1,27]]},"member":"276","prefix":"10.1212","source":"Crossref","volume":"106","created":{"date-time":"2025-12-17T21:00:10Z","timestamp":1766005210000,"date-parts":[[2025,12,17]]},"indexed":{"date-time":"2025-12-17T21:02:06Z","timestamp":1766005326394,"date-parts":[[2025,12,17]]},"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://www.neurology.org/doi/10.1212/WNL.0000000000214343"}},"subtitle":["Evidence From a 25-Year Prospective Cohort Study"],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-20"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-09"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-12-17"}],"deposited":{"date-time":"2025-12-17T21:00:14Z","timestamp":1766005214000,"date-parts":[[2025,12,17]]},"issn-type":[{"type":"print","value":"0028-3878"},{"type":"electronic","value":"1526-632X"}],"published":{"date-parts":[[2026,1,27]]},"publisher":"Ovid Technologies (Wolters Kluwer Health)","reference":[{"DOI":"10.1016/S2468-2667(21)00249-8","key":"e_1_3_8_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.phrs.2018.03.012","key":"e_1_3_8_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s13195-022-00957-1","key":"e_1_3_8_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu15010032","key":"e_1_3_8_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapsychiatry.2023.0800","key":"e_1_3_8_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.14283/jpad.2022.67","key":"e_1_3_8_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14132759","key":"e_1_3_8_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jalz.2018.12.011","key":"e_1_3_8_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2302368","key":"e_1_3_8_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/advances/nmab118","key":"e_1_3_8_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.advnut.2023.06.007","key":"e_1_3_8_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.advnut.2023.100160","key":"e_1_3_8_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3945/ajcn.116.151548","key":"e_1_3_8_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3389/fnut.2024.1366949","key":"e_1_3_8_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00394-022-02834-x","key":"e_1_3_8_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00394-023-03189-7","key":"e_1_3_8_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clnu.2023.08.019","key":"e_1_3_8_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jalz.2015.04.011","key":"e_1_3_8_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s11357-022-00615-2","key":"e_1_3_8_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu15143181","key":"e_1_3_8_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu16162800","key":"e_1_3_8_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu12020468","key":"e_1_3_8_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1212/01.wnl.0000183148.34197.2e","key":"e_1_3_8_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1212/01.wnl.0000278116.37320.52","key":"e_1_3_8_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00394-021-02688-9","key":"e_1_3_8_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/alz.12114","key":"e_1_3_8_27_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.tjpad.2025.100166","key":"e_1_3_8_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1474-4422(12)70291-0","key":"e_1_3_8_29_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10408398.2020.1867500","key":"e_1_3_8_30_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2796.1993.tb00647.x","key":"e_1_3_8_31_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/00008469-200112000-00003","key":"e_1_3_8_32_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_8_33_2","year":"1996","issue":null,"author":"Elmståhl S","volume":"50","first-page":"143","unstructured":"Elmståhl S, Riboli E, Lindgärde F, Gullberg B, Saracci R. The Malmö Food Study: the relative validity of a modified diet history method and an extensive food frequency questionnaire for measuring food intake. Eur J Clin Nutr. 1996;50:143-151.","article-title":"The Malmö Food Study: the relative validity of a modified diet history method and an extensive food frequency questionnaire for measuring food intake","journal-title":"Eur J Clin Nutr","doi-asserted-by":null},{"DOI":null,"key":"e_1_3_8_34_2","year":"1996","issue":null,"author":"Elmståhl S","volume":"50","first-page":"134","unstructured":"Elmståhl S, Gullberg B, Riboli E, Saracci R, Lindgärde F. The Malmö Food Study: the reproducibility of a novel diet history method and an extensive food frequency questionnaire. Eur J Clin Nutr. 1996;50:134-142.","article-title":"The Malmö Food Study: the reproducibility of a novel diet history method and an extensive food frequency questionnaire","journal-title":"Eur J Clin Nutr","doi-asserted-by":null},{"DOI":"10.3389/fnut.2021.779034","key":"e_1_3_8_35_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clnu.2024.09.026","key":"e_1_3_8_36_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1212/WNL.0000000000201336","key":"e_1_3_8_37_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3233/adr-220003","key":"e_1_3_8_38_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14061253","key":"e_1_3_8_39_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/ajcn/nqaa315","key":"e_1_3_8_40_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.neurobiolaging.2014.03.038","key":"e_1_3_8_41_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12986-018-0300-0","key":"e_1_3_8_42_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3402/fnr.v59.27651","key":"e_1_3_8_43_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3945/ajcn.116.134932","key":"e_1_3_8_44_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.idairyj.2016.04.006","key":"e_1_3_8_45_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/nu14142936","key":"e_1_3_8_46_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3168/jds.2024-25585","key":"e_1_3_8_47_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(20)30367-6","key":"e_1_3_8_48_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3233/JAD-215042","key":"e_1_3_8_49_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/joim.13728","key":"e_1_3_8_50_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2018.21554","key":"e_1_3_8_51_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"update-policy":"https://doi.org/10.1212/crossmarkpolicy","alternative-id":["10.1212/WNL.0000000000214343"],"article-number":"e214343","content-domain":{"domain":["www.neurology.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Neurology"],"published-print":{"date-parts":[[2026,1,27]]},"reference-count":50,"published-online":null,"references-count":50,"short-container-title":["Neurology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1212/wnl.0000000000214343","is_oa":true,"title":"High- and Low-Fat Dairy Consumption and Long-Term Risk of Dementia","updated":"2025-12-25T00:49:48+00:00","published_date":"2025-12-17","best_oa_location":{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12720290/","pmh_id":"oai:pubmedcentral.nih.gov:12720290","url_for_pdf":null,"url_for_landing_page":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12720290/"}}},"created_at":"2026-01-09T17:12:27.221Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"category","value":"Clinical Neurology","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"condition","value":"Alzheimer Disease","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"condition","value":"Vascular Dementia","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"sample_size","value":"n=27,670","value_numeric":27670},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"study_design","value":"Prospective Cohort","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"warning","value":"Covariate adjustments and stratifications are not described in the excerpt.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"warning","value":"Effect estimates for high-fat cream and low-fat dairy are not provided in the excerpt.","value_numeric":null},{"paper_doi":"10.1212/wnl.0000000000214343","tag_type":"warning","value":"The abstract sentence about the association with Alzheimer disease is truncated; details are missing.","value_numeric":null}],"summaries":{"what_studied":"A prospective cohort from the Malmö Diet and Cancer study in Sweden examined whether intake of high-fat vs low-fat dairy (assessed at baseline 1991–1996 with a 7-day diary, FFQ, and interview) was associated with risk of all-cause dementia, Alzheimer disease, and vascular dementia through linkage to national registers up to 2020.","key_result":"Over a median 25 years, 3,208 dementia cases occurred. Compared with <15 g/day, ≥50 g/day of high-fat cheese (>20% fat) was associated with lower all-cause dementia risk (HR 0.87, 95% CI 0.78–0.97) and lower vascular dementia risk (HR 0.71, 95% CI 0.52–0.96); higher high-fat cream intake was also linked to lower all-cause dementia risk, while low-fat dairy showed no significant association.","practice_takeaway":"When discussing diet and dementia risk, note that higher intake of high-fat cheese and cream correlated with lower all-cause dementia risk in this cohort, while low-fat dairy showed no association."}}],"initialOffset":15,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Vascular Dementia"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Vascular Dementia"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Vascular Dementia"}}}]]

Papers